🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07784270
Recruiting Phase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270 · tracked via the Priya Life Science Germany tracker
Phase
Phase 3
Started
2026-08-20
Last updated
2026-09-22

Condition(s) studied

Obesity or OverweightDiabetes Mellitus, Type 2

Investigational drug(s) / intervention(s)

AZD6234 →Placebo

AZD6234: IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Placebo: Placebo matching IMP dose injected subcutaneously, once a week.

Study summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Primary outcome measure(s)

Trial sites (227)

FacilityCityRegionStatus
Research Site Fairhope Alabama Recruiting
Research Site Huntsville Alabama Not Yet Recruiting
Research Site Mobile Alabama Not Yet Recruiting
Research Site Mesa Arizona Not Yet Recruiting
Research Site Phoenix Arizona Not Yet Recruiting
Research Site Tucson Arizona Not Yet Recruiting
Research Site Little Rock Arkansas Not Yet Recruiting
Research Site Bakersfield California Not Yet Recruiting
Research Site Gardena California Not Yet Recruiting
Research Site Lincoln California Recruiting
Research Site Torrance California Not Yet Recruiting
Research Site Walnut Creek California Not Yet Recruiting
Research Site Coral Gables Florida Not Yet Recruiting
Research Site Fleming Island Florida Not Yet Recruiting
Research Site Fort Lauderdale Florida Not Yet Recruiting
Research Site Ocoee Florida Not Yet Recruiting
Research Site Woodstock Georgia Not Yet Recruiting
Research Site Chicago Illinois Not Yet Recruiting
Research Site Melrose Park Illinois Not Yet Recruiting
Research Site Lenexa Kansas Recruiting
Research Site Newton Kansas Not Yet Recruiting
Research Site Monroe Louisiana Not Yet Recruiting
Research Site Beltsville Maryland Not Yet Recruiting
Research Site Lanham Maryland Not Yet Recruiting
Research Site Oxon Hill Maryland Not Yet Recruiting
Research Site Rockville Maryland Not Yet Recruiting
Research Site North Dartmouth Massachusetts Not Yet Recruiting
Research Site Farmington Hills Michigan Not Yet Recruiting
Research Site Fayette Mississippi Not Yet Recruiting
Research Site Kansas City Missouri Not Yet Recruiting
Research Site Kansas City Missouri Not Yet Recruiting
Research Site St Louis Missouri Not Yet Recruiting
Research Site Omaha Nebraska Not Yet Recruiting
Research Site Omaha Nebraska Not Yet Recruiting
Research Site Eatontown New Jersey Not Yet Recruiting
Research Site Somerset New Jersey Not Yet Recruiting
Research Site Warren Township New Jersey Not Yet Recruiting
Research Site Greensboro North Carolina Withdrawn
Research Site Monroe North Carolina Not Yet Recruiting
Research Site Kent Ohio Not Yet Recruiting

+ 187 more sites — see the full list on the official registry below.

More AstraZeneca trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07784270 on ClinicalTrials.gov ↗ ← All trials in Germany